AstraZeneca PLC (AZNCF)

Market Cap	196.63B
Revenue (ttm)	51.21B
Net Income (ttm)	6.50B
Shares Out	n/a
EPS (ttm)	4.15
PE Ratio	n/a
Forward PE	n/a
Dividend	1.00 (0.78%)
Ex-Dividend Date	Aug 8, 2024

Volume	n/a
Open	125.50
Previous Close	124.70
Day's Range	125.50 - 125.50
52-Week Range	118.16 - 175.00
Beta	0.17
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2024

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1992
• Employees: 89,900
• Stock Exchange: OTCMKTS
• Ticker Symbol: AZNCF

Financial Performance

In 2023, AstraZeneca's revenue was $45.81 billion, an increase of 3.29% compared to the previous year's $44.35 billion. Earnings were $5.96 billion, an increase of 81.11%.